Marshall Wace’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-30,900
| Closed | -$1.59M | – | 3873 |
|
|
2022
Q3 | $1.59M | Sell |
30,900
-1,148,048
| -97% | -$47.5M | ﹤0.01% | 2156 |
|
|
2022
Q2 | $29.2M | Sell |
1,178,948
-219,635
| -16% | -$4.84M | 0.06% | 334 |
|
|
2022
Q1 | $35.1M | Buy |
1,398,583
+569,585
| +69% | +$16M | 0.07% | 326 |
|
|
2021
Q4 | $30.2M | Buy |
+828,998
| New | +$29.1M | 0.06% | 350 |
|
|
2020
Q3 | – | Sell |
-121,003
| Closed | -$6.96M | – | 2029 |
|
|
2020
Q2 | $6.96M | Buy |
121,003
+108,919
| +901% | +$5.93M | 0.05% | 385 |
|
|
2020
Q1 | $486K | Sell |
12,084
-40,186
| -77% | -$1.71M | ﹤0.01% | 981 |
|
|
2019
Q4 | $2.07M | Buy |
+52,270
| New | +$918K | 0.01% | 804 |
|
|
2019
Q2 | – | Sell |
-132,410
| Closed | -$1.84M | – | 1987 |
|
|
2019
Q1 | $1.84M | Buy |
+132,410
| New | +$1.51M | 0.02% | 766 |
|
|
2015
Q4 | – | Sell |
-282,713
| Closed | -$1.71M | – | 1171 |
|
|
2015
Q3 | $1.71M | Hold |
282,713
| – | – | 0.02% | 492 |
|
|
2015
Q2 | $2.33M | Buy |
282,713
+55,055
| +24% | +$437K | 0.03% | 441 |
|
|
2015
Q1 | $1.72M | Buy |
+227,658
| New | +$1.78M | 0.02% | 494 |
|
|
2014
Q3 | – | Sell |
-98,298
| Closed | -$575K | – | 1091 |
|
|
2014
Q2 | $575K | Buy |
+98,298
| New | +$552K | 0.01% | 581 |
|
Other funds holding CCXI
Marshall Wace's CCXI Position: Q4 2022 in Review
Marshall Wace sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 30,900 shares — an estimated $1.59M sold.
Marshall Wace first reported a position in CCXI in Q2 2014 and held it in 12 quarters. The position peaked at $35.1M in Q1 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Marshall Wace reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Marshall Wace sold 30,900 ChemoCentryx, Inc. shares in Q4 2022, an estimated $1.59M.
- Marshall Wace first reported a position in ChemoCentryx, Inc. in Q2 2014 and held it in 12 quarters.
- Marshall Wace's ChemoCentryx, Inc. position peaked at $35.1M in Q1 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.